Women's Health Initiative | Baseline CVD Biomarkers

Baseline CVD Biomarkers

A subset of WHI participants have CVD biomarkers at baseline through a core set of WHI studies (additional participants have had CVD biomarkers measured through smaller ancillary studies, but those are not described here). A description of the participants with both CVD biomarker data and imputed GWAS data can be found here.

	Baseline CVD Biomarkers – subset of WHI core analytesSerum: glucose and insulin EDTA plasma: lipidsCreatinine and CRP were NOT measuredLab: MRL/PPD	Baseline CVD Biomarkers Serum: glucose, insulin, lipids, creatinine and CRP Lab: University of Minnesota (UMMC)
	W1: 6% CT subsample	W2: 1% OS Measurement Precision study	W54: African American and Hispanic	W58: European American HT	W66: LLS eligibility pool expansion	AS422: Native American
	N=~4,546	N=~1,082	N=~12,157	N=~10,306	N=~1,502	N=~594	Total ~N
A. Original CVD Biomarker Cohort (selected to be a representative subsample of WHI, tested at UMMC)			X	X			22,463
B. All CVD biomarkers tested at UMMC			X	X	X	X	24,558
C. Core analyte subcohort (tested at MRL/PPD)	X	X					5,628
D. All (tested at MRL/PPD and/or UMMC)	X	X	X	X	X	X	27,544

Note:

Counts are of the participants selected for a study, not the number with specimen results. A small number of participants selected for a study may not have results for one or more assays due to insufficient sample or assay failure.

2,642 participants overlap between options B and C.

It is important to note that CVD Biomarkers were measured at two different labs using different methods. ~5,600 participants had baseline CVD biomarkers (plasma: lipids, serum: glucose and insulin) measured at MRL/PPD as a subset of the WHI core analytes measured in studies W1 (6% CT subsample) and W2 (1% OS measurement Precision Study). ~24,500 participants had baseline CVD biomarkers (Laboratory Methods: serum: lipids, glucose, insulin, creatinine, and CRP) measured at UMMC in studies W54 (African Americans and Hispanics), W58 (European Americans in the HT), W66 (LLS eligibility pool expansion), and AS422 (Native Americans). W54 and W58 together are often referred to as the “CVD Biomarker Cohort”, but W66 and AS422 also contribute to the baseline CVD biomarker resource.

The WHI blood draws were scheduled to be fasting draws, but in some cases participants were not fasting. Fasting status is indicated in the WHI database.

The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services.